Pharmaceutical

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF)…

8 months ago
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot StudyRecce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study

Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study

RECCE® 327 (R327) demonstrated >99% log reduction (>2.5 log reduction) in Mycobacterium abscessus lung infections using a nebulizer delivery methodR327…

8 months ago
IMUNON Reports First Quarter 2024 Financial Results and Provides Business UpdateIMUNON Reports First Quarter 2024 Financial Results and Provides Business Update

IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:…

8 months ago
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor ConferenceDisc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference

Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference

WATERTOWN, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,…

8 months ago
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated MilestonesAnnexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected…

8 months ago
Collegium Announces $35 Million Accelerated Share Repurchase ProgramCollegium Announces $35 Million Accelerated Share Repurchase Program

Collegium Announces $35 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed…

8 months ago
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate DevelopmentsBarinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

OXFORD, United Kingdom, May 13, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel…

8 months ago
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceX4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people…

8 months ago
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic DermatologyExpert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

Eight of nine experts expressed feeling “extremely confident” about prescribing ZORYVE foam to patients of diverse skin and hair types,…

8 months ago
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate UpdateCompass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with…

8 months ago